Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Vascular Biogen. Ord (VBLT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 63,644
  • Shares Outstanding, K 29,950
  • Annual Sales, $ 13,860 K
  • Annual Income, $ -10,140 K
  • 36-Month Beta -1.71
  • Price/Sales 4.59
  • Price/Cash Flow N/A
  • Price/Book 1.26

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.00 +5.00%
on 07/19/18
2.80 -25.00%
on 06/20/18
-0.70 (-25.00%)
since 06/19/18
3-Month
2.00 +5.00%
on 07/19/18
3.10 -32.26%
on 06/06/18
-0.10 (-4.55%)
since 04/19/18
52-Week
2.00 +5.00%
on 07/19/18
9.05 -76.80%
on 11/16/17
-2.10 (-49.94%)
since 07/19/17

Most Recent Stories

More News
Publication by VBL Therapeutics Highlights MOSPD2 as a Potential New Target for Breast Cancer Therapy

Paper on Role of MOSPD2 in Metastatic Breast Cancer Published in International Journal of Cancer

VBLT : 2.10 (-1.18%)
VBL Therapeutics Announces Closing of $15.5 Million Registered Direct Offering

VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced the closing...

VBLT : 2.10 (-1.18%)
VBL Therapeutics Announces $15.5 Million Registered Direct Offering Priced At-the-Market

VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it has...

VBLT : 2.10 (-1.18%)
Breakfast Technical Briefing on Tesaro and Three Other Additional Biotech Stocks

Stock Research Monitor: TLGT, VBLT, andVTGN

TLGT : 4.01 (-1.23%)
TSRO : 40.23 (-1.78%)
VBLT : 2.10 (-1.18%)
Today's Research Reports on Stocks to Watch: Enanta Pharmaceuticals and Vascular Biogenics

NEW YORK, NY / ACCESSWIRE / June 7, 2018 / Enanta Pharmaceuticals as well as Vascular Biogenics were two stocks in the biotech arena making big moves in Wednesday's trading session. Enanta climbed higher...

ENTA : 123.13 (-1.97%)
VBLT : 2.10 (-1.18%)
VBL Therapeutics Presents Positive Data on its MOSPD2 Platform Technology in Oncology and Inflammation at BIO 2018

VBL Therapeutics (NASDAQ:VBLT) today presented data on its novel MOSPD2 program in oncology and inflammation at the 2018 BIO International Convention in Boston, Massachusetts.

VBLT : 2.10 (-1.18%)
VBL Therapeutics to Present at Upcoming Conferences in June

VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that the Company...

VBLT : 2.10 (-1.18%)
VBL Therapeutics to Present Data on its MOSPD2 Oncology Program at MIXiii-BIOMED 2018 on May 15

VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will...

VBLT : 2.10 (-1.18%)
VBL Therapeutics to Report First Quarter 2018 Financial Results on May 17

VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will...

VBLT : 2.10 (-1.18%)
Vascular Biogenics (VBLT) Enters Oversold Territory

Vascular Biogenics Ltd. (VBLT) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock

VBLT : 2.10 (-1.18%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade VBLT with:

Business Summary

Vascular Biogenics Ltd. is a clinical stage biotechnology company. It is focused on the discovery, development and commercialization of treatments for cancer and immune-inflammatory diseases. Its lead oncology candidate VB-111, is a gene-based biologic which is in Phase II clinical trials for the treatment...

See More

Key Turning Points

2nd Resistance Point 2.23
1st Resistance Point 2.17
Last Price 2.10
1st Support Level 2.02
2nd Support Level 1.93

See More

52-Week High 9.05
Fibonacci 61.8% 6.36
Fibonacci 50% 5.53
Fibonacci 38.2% 4.69
Last Price 2.10
52-Week Low 2.00

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar